Who Owns Autolus Therapeutics Stock?
NASDAQ: AUTLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 56.45%
- Held by insiders
- 18.73%
- Institutional holders
- 106
- Institutions 56.5%
- Insiders 18.7%
- Public and other 24.8%
Who owns Autolus Therapeutics stock?
Institutional investors own about 56.5% of Autolus Therapeutics's shares, spread across 106 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 18.73% of AUTL.
The largest institutional holders are MAK Capital One LLC (12.62%), Blackstone Inc (7.69%) and Syncona Portfolio Ltd (6.25%). Together, the top 10 institutions control 43.8% of shares outstanding. In their latest filings, 1 of the top 10 institutions increased their AUTL positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of AUTL
| Institution | Shares | % Held | Change |
|---|---|---|---|
| MAK Capital One LLC | 33.62M | 12.62% | 0.0% |
| Blackstone Inc | 20.49M | 7.69% | 0.0% |
| Syncona Portfolio Ltd | 16.64M | 6.25% | 0.0% |
| Armistice Capital, LLC | 15.00M | 5.63% | -5.1% |
| Tetragon Partners GP Ltd. | 9.50M | 3.57% | 0.0% |
| Schroder Investment Management Group | 7.83M | 2.94% | -17.4% |
| Frazier Life Sciences Management, L.P. | 4.45M | 1.67% | 0.0% |
| BNP Paribas Asset Management Holding S.A. | 3.36M | 1.26% | 0.0% |
| Laurion Capital Management, LP | 3.32M | 1.25% | 0.0% |
| Renaissance Technologies, LLC | 2.49M | 0.94% | +25.6% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of AUTL
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Biotechnology ETF | 1.34M | 0.50% |
| Tema ETF Trust-Tema Oncology ETF | 268.13K | 0.10% |
| SPDR INDEX SHARES Fd.S-State Street SPDR S&P Intl Small Cap ETF | 101.95K | 0.04% |
| Invesco Exch-Trd Fd. TRT II-Invesco NASDAQ Future Gen 200 ETF | 50.74K | 0.02% |
| Trust for Professional Managers-ActivePassive International Equity ETF | 31.58K | 0.01% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 13.36K | 0.01% |
| Invesco Exchange-Traded Fund Trust II-Invesco Nasdaq Biotechnology ETF | 12.42K | 0.00% |
| ProShares Trust-ProShares Ultra Nasdaq Biotechnology | 8.01K | 0.00% |
Frequently asked questions
Who is the largest shareholder of Autolus Therapeutics?
MAK Capital One LLC is the largest institutional shareholder of AUTL, owning 12.62% of shares outstanding (33.62M shares) as of its latest 13F filing.
What percentage of Autolus Therapeutics is owned by institutions?
Institutions own about 56.5% of AUTL shares and 69.5% of the public float.
How much of Autolus Therapeutics do insiders own?
Insiders, such as officers and directors, own about 18.73% of AUTL shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.